Dr. Larry Ereshefsky Featured Speaker in Webinar
Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced it will host a webinar exploring the use of a common clinical measure, Event-Related Potential P300 latency (P300), as an assessment of working memory processing speed. The webinar will be webcast live on Wednesday, Oct. 28, at 1 p.m. PT / 4 p.m.ET and will feature:
● A discussion with Larry Ereshefsky, Pharm.D., BCPP, FCCP, a leader in the application of translational drug development tools for neurodegenerative and psychiatric disorders. Dr. Ereshefsky is Chief Scientific Officer at Apex Innovative Sciences and a member of Athira’s Scientific Advisory Board.
● Leen Kawas, Ph.D., President and Chief Executive Officer at Athira, who will review the company’s completed and ongoing Phase 2/3 clinical trials of ATH-1017.
Athira is measuring P300 in clinical trials of its investigational drug, ATH-1017, for treatment of mild-to-moderate Alzheimer’s disease to establish a connection between this functional measurement and improved cognition.
The live webcast event can be accessed from the investors’ section of the Athira website at https://investors.athira.com/news-and-events/events-and-presentations. An archived replay will also be available on the company website for at least 30 days following the event.